Cargando…
Association Between NAT2 Polymorphism and Lung Cancer Risk: A Systematic Review and Meta-Analysis
Lung cancer is the leading cause of cancer-related death worldwide and has a high incidence rate. N-Acetyltransferase 2 (NAT2) is a polymorphic xenobiotic enzyme, which can catalyze N-acetylation and O-acetylation of various carcinogens such as aromatic, heterocyclic amines and hydrazines. At presen...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991837/ https://www.ncbi.nlm.nih.gov/pubmed/33777732 http://dx.doi.org/10.3389/fonc.2021.567762 |
_version_ | 1783669252456185856 |
---|---|
author | Zhu, Ke Xu, Aiqun Xia, Wanli Li, Pulin Zhang, Binbin Jiang, Huihui Zhou, Sijing Wang, Ran |
author_facet | Zhu, Ke Xu, Aiqun Xia, Wanli Li, Pulin Zhang, Binbin Jiang, Huihui Zhou, Sijing Wang, Ran |
author_sort | Zhu, Ke |
collection | PubMed |
description | Lung cancer is the leading cause of cancer-related death worldwide and has a high incidence rate. N-Acetyltransferase 2 (NAT2) is a polymorphic xenobiotic enzyme, which can catalyze N-acetylation and O-acetylation of various carcinogens such as aromatic, heterocyclic amines and hydrazines. At present, many studies have explored the effects of NAT2 polymorphism on lung cancer, but we found inconsistent results. We researched 18 published studies, involving 4,016 patients and 5,469 controls, to more accurately assess the effects of NAT2 polymorphism on lung cancer risk and to investigate whether smoking is associated. We used STATA software to analyze the extracted data and used STATA for subgroup analysis, sensitivity analysis, and to perform publication bias tests. To determine the correlation, we used the crude odds ratio (ORs) with 95% confidence interval (CIs). Our study was prospectively registered in PROSPERO (CRD42020159737). The odds ratio was 1.53 (95% CI: 1.21–1.95, I² = 45.2%, P=0.104) for the NAT2 slow + intermediate phenotype versus rapid phenotype. The results suggested that people with NAT2 non-rapid (slow + intermediate) phenotype have a significantly increased risk of lung cancer. In addition, NAT2 rapid phenotype was significantly associated with reduced risk of lung cancer, compared with slow phenotype or intermediate phenotype (slow phenotype vs. rapid phenotype: OR: 1.61, 95% CI: 1.07–2.42, I²= 50%, P= 0.075; intermediate phenotype vs. rapid phenotype: OR: 1.47, 95% CI: 1.15–1.88, I²= 40.3%, P= 0.137). |
format | Online Article Text |
id | pubmed-7991837 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79918372021-03-26 Association Between NAT2 Polymorphism and Lung Cancer Risk: A Systematic Review and Meta-Analysis Zhu, Ke Xu, Aiqun Xia, Wanli Li, Pulin Zhang, Binbin Jiang, Huihui Zhou, Sijing Wang, Ran Front Oncol Oncology Lung cancer is the leading cause of cancer-related death worldwide and has a high incidence rate. N-Acetyltransferase 2 (NAT2) is a polymorphic xenobiotic enzyme, which can catalyze N-acetylation and O-acetylation of various carcinogens such as aromatic, heterocyclic amines and hydrazines. At present, many studies have explored the effects of NAT2 polymorphism on lung cancer, but we found inconsistent results. We researched 18 published studies, involving 4,016 patients and 5,469 controls, to more accurately assess the effects of NAT2 polymorphism on lung cancer risk and to investigate whether smoking is associated. We used STATA software to analyze the extracted data and used STATA for subgroup analysis, sensitivity analysis, and to perform publication bias tests. To determine the correlation, we used the crude odds ratio (ORs) with 95% confidence interval (CIs). Our study was prospectively registered in PROSPERO (CRD42020159737). The odds ratio was 1.53 (95% CI: 1.21–1.95, I² = 45.2%, P=0.104) for the NAT2 slow + intermediate phenotype versus rapid phenotype. The results suggested that people with NAT2 non-rapid (slow + intermediate) phenotype have a significantly increased risk of lung cancer. In addition, NAT2 rapid phenotype was significantly associated with reduced risk of lung cancer, compared with slow phenotype or intermediate phenotype (slow phenotype vs. rapid phenotype: OR: 1.61, 95% CI: 1.07–2.42, I²= 50%, P= 0.075; intermediate phenotype vs. rapid phenotype: OR: 1.47, 95% CI: 1.15–1.88, I²= 40.3%, P= 0.137). Frontiers Media S.A. 2021-03-11 /pmc/articles/PMC7991837/ /pubmed/33777732 http://dx.doi.org/10.3389/fonc.2021.567762 Text en Copyright © 2021 Zhu, Xu, Xia, Li, Zhang, Jiang, Zhou and Wang http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Zhu, Ke Xu, Aiqun Xia, Wanli Li, Pulin Zhang, Binbin Jiang, Huihui Zhou, Sijing Wang, Ran Association Between NAT2 Polymorphism and Lung Cancer Risk: A Systematic Review and Meta-Analysis |
title | Association Between NAT2 Polymorphism and Lung Cancer Risk: A Systematic Review and Meta-Analysis |
title_full | Association Between NAT2 Polymorphism and Lung Cancer Risk: A Systematic Review and Meta-Analysis |
title_fullStr | Association Between NAT2 Polymorphism and Lung Cancer Risk: A Systematic Review and Meta-Analysis |
title_full_unstemmed | Association Between NAT2 Polymorphism and Lung Cancer Risk: A Systematic Review and Meta-Analysis |
title_short | Association Between NAT2 Polymorphism and Lung Cancer Risk: A Systematic Review and Meta-Analysis |
title_sort | association between nat2 polymorphism and lung cancer risk: a systematic review and meta-analysis |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991837/ https://www.ncbi.nlm.nih.gov/pubmed/33777732 http://dx.doi.org/10.3389/fonc.2021.567762 |
work_keys_str_mv | AT zhuke associationbetweennat2polymorphismandlungcancerriskasystematicreviewandmetaanalysis AT xuaiqun associationbetweennat2polymorphismandlungcancerriskasystematicreviewandmetaanalysis AT xiawanli associationbetweennat2polymorphismandlungcancerriskasystematicreviewandmetaanalysis AT lipulin associationbetweennat2polymorphismandlungcancerriskasystematicreviewandmetaanalysis AT zhangbinbin associationbetweennat2polymorphismandlungcancerriskasystematicreviewandmetaanalysis AT jianghuihui associationbetweennat2polymorphismandlungcancerriskasystematicreviewandmetaanalysis AT zhousijing associationbetweennat2polymorphismandlungcancerriskasystematicreviewandmetaanalysis AT wangran associationbetweennat2polymorphismandlungcancerriskasystematicreviewandmetaanalysis |